Douglas Kell Explained

Douglas Kell
Birth Name:Douglas Bruce Kell
Birth Date:7 April 1953
Nationality:British
Education:Bradfield College
Alma Mater:University of Oxford (BA, DPhil)
Thesis Title:The Bioenergetics of Paracoccus denitrificans
Thesis Url:https://ora.ox.ac.uk/objects/uuid:0209c2a9-74bd-43db-9a00-f2ffc1fc2e9c
Thesis Year:1978
Known For:CEO of BBSRC
Prizes:Fellow of the American Association for the Advancement of Science (2012)[1]
Children:3

Douglas Bruce Kell (born 7 April 1953) is a British biochemist and Professor of Systems Biology in the Institute of Systems, Molecular and Integrative Biology at the University of Liverpool. He was previously at the School of Chemistry at the University of Manchester, based in the Manchester Institute of Biotechnology (MIB)[2] where he founded and led the Manchester Centre for Integrative Systems Biology (MCISB). He served as chief executive officer (CEO) of the Biotechnology and Biological Sciences Research Council (BBSRC) from 2008 to 2013.[3] [4] [5] [6]

Education and early life

Kell was privately educated at Hydneye House in Sussex[7] and Bradfield College in Berkshire where he was top scholar. He graduated from the University of Oxford with a Bachelor of Arts degree in Biochemistry in 1975 with a distinction in chemical pharmacology, where he was an undergraduate student of St John's College, Oxford. He stayed in Oxford for his Doctor of Philosophy degree, completed in 1978 with a thesis on the bioenergetics of the microbe Paracoccus denitrificans, supervised by Stuart Ferguson[8] [9] and Philip John.[10]

Research and career

From 1978 to 2002 he worked at Aberystwyth University, moving to the University of Manchester Institute of Science and Technology (UMIST) in 2002 as an Engineering and Physical Sciences Research Council (EPSRC) / Royal Society of Chemistry (RSC) Research Chair in Bioanalytical Sciences. (UMIST merged with the Victoria University of Manchester in 2004, to become the University of Manchester.) He moved to the University of Liverpool in 2018 to work in the Johnston Laboratories, which were the world's first department of biochemistry at a University.

Kell's primary research interests are in systems biology, synthetic biology and computational biology. He has also been involved in the development of multivariate scientific instrumentation and the attendant machine learning software (his first paper on artificial neural networks was in 1992). He has written extensively on the role of microbes as agents of supposedly 'non-communicable', chronic infectious diseases. His publications are mostly open access and are very widely cited, with an H-index at Google Scholar in excess of 130. According to Google Scholar his most cited peer-reviewed research papers are in functional genomics,[11] metabolomics[12] and the yeast genome.[13] He has also been involved in research to create a robot scientist[14] in collaboration with Ross King, Stephen Muggleton and Steve Oliver, as well as several projects in systems biology.[15] [16] [17] He is involved in the study of membrane transporters, and their necessary involvement in the transmembrane uptake of pharmaceutical drugs.[18] He tends to choose scientific problems in which the prevailing orthodoxy is clearly incorrect. To this end, he has recently returned to the study of bioenergetics, summarising the detailed evidence against the prevailing wisdom of chemiosmotic coupling in oxidative and photosynthetic phosphorylation, replacing it with a protet-based model.[19] [20]

With his collaborator Resia Pretorius, Kell discovered the amyloidogenic clotting of blood, involving the amyloidogenic self-assembly of the clotting protein fibrin into highly stable β-sheets that — unlike regular clots — are resistant to plasmin, the enzyme responsible for breaking up clots (fibrinolysis).[21] They report that such amyloidogenic clotting appears to be mostly caused by infectious agents, even in supposedly non-infectious diseases.[22] Kell and Pretorius report that such fibrin amyloid microclots (fibrinaloids) seem to be of major significance in long COVID.[23]

In 1988, he was a founding director of Aber Instruments, based at Aberystwyth Science Park (originally at the Centre for Alternative Technology (CAT), Machynlleth, Wales). In 2019 he was a co-founding director of Mellizyme Ltd, now Epoch Biodesign;[24] he left the company in 2023. He cofounded PhenUTest Ltd in 2021. He is an Associated Scientific Director of the Centre for Biosustainability at the Technical University of Denmark, where he runs the Flux Optimisation and Bioanalytics Group.

Kell's research has been funded by the European Union (EU), the BBSRC, the Medical Research Council (MRC) and the Engineering and Physical Sciences Research Council (EPSRC).[25] [26] His former doctoral students and postdoctoral researchers include Pedro Mendes. His monograph Belief: the baggage behind our being was published in 2018.[27] [28]

Awards and honours

Kell was appointed Commander of the Order of the British Empire (CBE) in the 2014 New Year Honours, for services to science and research. Kell is also a Fellow of the Learned Society of Wales (FLSW), a Fellow of the Royal Society of Biology (FRSB) and a Fellow of the American Association for the Advancement of Science (FAAS).[1]

References

|-

Notes and References

  1. Web site: AAAS - 2012 Fellows . 23 March 2013 . https://web.archive.org/web/20130323142745/http://www.aaas.org/aboutaaas/fellows/2012.shtml . dead.
  2. Web site: Prof Douglas Kell, research profile - personal details. University of Manchester. https://web.archive.org/web/20120314025208/http://www.manchester.ac.uk/research/Douglas.kell. 2012-03-14. Douglas. Kell. 2012 . 2012-06-12.
  3. Web site: 19 June 2012 - Reappointment of Chief Executive for the Biotechnology and Biological Sciences Research Council - News - BBSRC . 26 June 2012 . https://web.archive.org/web/20120626131438/http://www.bbsrc.ac.uk/news/people-skills-training/2012/120619-n-reappointment-of-chief-executive.aspx . dead.
  4. Web site: Van Noorden . Richard . Interview: Douglas Kell. Chemistry World . 2008-11-24 . 2017-06-07.
  5. http://www.rsc.org/Publishing/Journals/cb/Volume/2008/11/Douglas_Kell.asp Interview with Douglas Kell
  6. 25505138. 2015. Kell. D. B.. The virtue of innovation: Innovation through the lenses of biological evolution. Journal of the Royal Society Interface. 12. 103. 20141183. Lurie-Luke. E. 10.1098/rsif.2014.1183 . 4305420.
  7. Web site: Hydneye House - a set on Flickr . 23 January 2013 . https://archive.today/20130123031214/http://www.flickr.com/photos/87532379@N00/sets/72157601748764095/ . dead. 18 January 2017 .
  8. Kell . D.. Douglas Kell . John . P. . Ferguson . S. . The protonmotive force in phosphorylating membrane vesicles from Paracoccus denitrificans. Magnitude, sites of generation and comparison with the phosphorylation potential . . 174 . 1 . 257–266 . 1978 . 212022 . 1185905 . 10.1042/bj1740257.
  9. Web site: Prof Stuart Ferguson Page - Department of Biochemistry, University of Oxford . 20 May 2013 . https://web.archive.org/web/20130520134520/http://www.bioch.ox.ac.uk/aspsite/index.asp?pageid=576 . dead.
  10. DPhil. Douglas Bruce. Kell. The bioenergetics of paracoccus denitrificans. University of Oxford. 1978. ora.ox.ac.uk. Douglas Kell. . 863351446.
  11. Oliver . S. G. . Stephen Oliver (scientist). Teusink . L. M. . Broadhurst . B. . Zhang . D. . Hayes . N. . Walsh . A. . Berden . M. C. . Brindle . J. A. . Kell . K. M. . Rowland . D. B. . Westerhoff . J. J. . Van Dam . H. V. . Oliver . K. . A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations . Nature Biotechnology . 19 . 1 . 45–50 . 10.1038/83496 . 2001 . 11135551 . 15491882 .
  12. Goodacre . R. . Vaidyanathan . S. . Dunn . W. B. . Harrigan . G. G. . Kell . D. B. . Douglas Kell. Metabolomics by numbers: Acquiring and understanding global metabolite data . 10.1016/j.tibtech.2004.03.007 . Trends in Biotechnology . 22 . 5 . 245–252 . 2004 . 15109811 .
  13. Oliver . S. . Stephen Oliver (scientist). Winson . M. . Kell . D. . Douglas Kell. Baganz . F. . Systematic functional analysis of the yeast genome . Trends in Biotechnology . 16 . 9 . 373–378 . 1998 . 9744112 . 10.1016/S0167-7799(98)01214-1. 10.1.1.33.5221 .
  14. King . R. D. . Ross D. King. Whelan . K. E. . Jones . F. M. . Reiser . P. G. K. . Bryant . C. H. . Muggleton . S. H. . Stephen Muggleton. Kell . D. B. . Douglas Kell. Oliver . S. G.. Stephen Oliver (scientist) . 10.1038/nature02236 . Functional genomic hypothesis generation and experimentation by a robot scientist. . 427 . 6971 . 247–252 . 2004 . 14724639 . 2004Natur.427..247K . 4428725 .
  15. Kell . Douglas . Douglas Kell. Journal club: A systems biologist ponders how disparate ideas can sometimes come together beautifully . 10.1038/460669e . Nature . 460 . 7256 . 669 . 2009 . 19661875 . 2009Natur.460..669K . 1857476 . free .
  16. Dobson . P. D. . Smallbone . K. . Jameson . D. . Simeonidis . E. . Lanthaler . K. . Pir . P.. Lu . C. . Swainston . N.. Dunn . W. B. . Fisher . P. . Hull . D. . Brown . M. . Oshota . O. . Stanford . N. J. . Kell . D. B. . King . R. D. . Oliver . S. G. . Stevens . R. D. . Mendes . P. . Further developments towards a genome-scale metabolic model of yeast . 10.1186/1752-0509-4-145 . BMC Systems Biology . 4 . 145 . 2010 . 21029416 . 2988745 . free .
  17. Pir . P. . Gutteridge . A. . Wu . J. . Rash . B. . Kell . D. B. . Douglas Kell. Zhang . N. . Oliver . S. G. . Stephen Oliver (scientist). The genetic control of growth rate: A systems biology study in yeast . 10.1186/1752-0509-6-4 . BMC Systems Biology . 6 . 4 . 2012 . 22244311 . 3398284. free .
  18. Web site: How Drugs Really Get Into Cells: Why Passive Bilayer Diffusion is a Myth. https://web.archive.org/web/20210415135220/https://www.acs.org/content/acs/en/acs-webinars/drug-discovery/so-lute-carriers.html. dead. 15 April 2021. 30 April 2020.
  19. Web site: Protet_PCT model of ETP. 9 February 2020. Kell . Douglas Bruce .
  20. Book: Advances in Microbial Physiology . Kell . Douglas B. . A protet-based, protonic charge transfer model of energy coupling in oxidative and photosynthetic phosphorylation . 2021 . 78 . 1–177 . Elsevier . 0065-2911 . 10.1016/bs.ampbs.2021.01.001 . 34147184 . 9780128246016 . 234894761 .
  21. Pretorius E, Mbotwe S, Bester J, Robinson CJ, Kell DB . Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide . J R Soc Interface . September 2016 . 13 . 122 . 20160539 . 10.1098/rsif.2016.0539 . 27605168 . 5046953.
  22. 10.1016/j.pbiomolbio.2016.08.006 . 2017 . Kell . Douglas B. . Pretorius . Etheresia . Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting . 123 . 6–41 . Prog. Biophys. Mol. Biol.. 27554450 . 2263/59001 . free .
  23. Kell . Douglas B. . Laubscher . Gert Jacobus . Pretorius . Etheresia . A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications . Biochemical Journal . 23 February 2022 . 479 . 4 . 537–559 . 0264-6021 . 1470-8728 . 10.1042/BCJ20220016 . 35195253 . 8883497 .
  24. Web site: Epoch BioDesign. epochbiodesign.com .
  25. http://gtr.rcuk.ac.uk/person/8B8EA445-E75D-4708-972F-A10DF88F5961 UK Government Grants awarded to Douglas Kell
  26. http://gow.epsrc.ac.uk/NGBOViewPerson.aspx?PersonId=8693 Grants awarded to Douglas Kell
  27. Web site: We have written a free book (monograph) on why people believe crazy things, including #Brexit .. Kell. Doug. 15 March 2018. Twitter @dbkell. en. 2018-03-19.
  28. Kell DB, Welch GR (2018) Belief: thebaggage behind our being. OSF preprints

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Douglas Kell".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.